Log In
BCIQ
Print this Print this
 

PEG-SN38 conjugate (PL0264)

  Manage Alerts
Collapse Summary General Information
Company ProLynx LLC
DescriptionPegylated form of SN38, the active metabolite of irinotecan
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today